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Abstract
Chronic kidney disease and cardiovascular disease share many risk factors. Injury to the vascular
endothelium, measured by elevated levels of serum C-reactive protein (CRP), may play a role in
kidney and cardiovascular disease. We therefore examined the association of CRP with
microalbuminuria, a marker of early kidney injury. We conducted a cross-sectional analysis of a
nationally representative, population-based survey. Weighted multiple logistic regression was used
to study the association between CRP and microalbuminuria, adjusting for well-known risk factors.
CRP was analyzed by a continuous variable and two categorized variables using quartiles and
clinically recommended cutpoints. CRP concentration was positively associated with
microalbuminuria. In the multivariate model, a one unit (in milligrams per liter) increase in CRP
concentration was associated with a 2% increased odds of microalbuminuria (odds ratio 1.02, 95%
confidence interval [CI] 1.01 to 1.02, p = 0.0003). When CRP concentrations were stratified by
clinically recommended cutpoints, compared with persons with CRP concentrations <1 mg/dl,
persons with CRP concentrations between 1 and 3 mg/L and >3 mg/L were 1.15 times (95% CI 0.94
to 1.42) and 1.33 times (95% CI 1.08 to 1.65) more likely to have microalbuminuria, respectively.
In subgroup analyses, the strength of association was comparable or stronger. In conclusion, elevated
CRP levels were associated with microalbuminuria in a large, nationally representative data set.
Vascular inflammation, as measured by CRP, may be a common contributor to early heart and kidney
disease.
© 2008 Elsevier Inc. All rights reserved.
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Chronic kidney disease and cardiovascular disease share many risk factors. The similarities in
the pathogenesis of cardiovascular and chronic kidney disease suggest that vascular
inflammation may have a role in kidney dysfunction. We postulated that C-reactive protein
(CRP) is positively associated with microalbuminuria, an easily measured and widely used
marker of early kidney injury. Although preliminary supportive evidence exists, the studies
are limited by significant methodologic issues including small sample sizes,1–5 the presence
of confounding variables,6 lack of generalizability,7 and the use of indirect comparisons.8–
10 We therefore examined the association of CRP and microalbuminuria in a large, diverse
data set compiled from the National Health and Nutrition Examination Surveys (NHANES)
1999 through 2004.
Methods
NHANES are national surveys conducted since 1971 by the National Center for Health
Statistics of the Centers for Disease Control and Prevention (CDC). Participants in NHANES
are identified through a complex, multistage clustering sample design of the civilian,
noninstitutionalized population. Certain under-represented populations, such as older people,
racial–ethnic minorities, and low income families, were oversampled. We combined data from
3 independent surveys, available on a public domain website
(http://www.cdc.gov/nchs/nhanes.htm), for a total of 6 years: NHANES 1999 to 2000, 2001
to 2002, and 2003 to 2004. For our analysis, we restricted the NHANES population to the adult
population of men and women aged ≥20 years.
NHANES used trained personnel to ascertain medical and health information from participants
by direct interview, examination, and blood samples. We chose comprehensive
sociodemographic and clinical variables as potential confounders of the association between
CRP and microalbuminuria based on the literature. These included demographic factors (age,
gender, race, education), family history of diabetes and hypertension, and personal health
history (cholesterol, blood pressure, diabetes mellitus, body mass index [BMI], smoking status,
and glomerular filtration rate) (see Table 1 for a complete list).
For the study end point, we first generated a urinary albumin-to-creatinine ratio and then
defined microalbuminuria as a ratio between 30 and 300 mg/g. Participants with ratios >300
mg/g (i.e., with macroalbuminuria) were excluded from the primary analysis. Various
characteristics between persons with microalbuminuria and persons without microalbuminuria
were compared. Unadjusted means along with standard errors for continuous variables and
proportions for categorical variables were calculated by case status. The differences were tested
by t test or Wald chi-square tests, suited for complex survey design.11 Key demographic factors
(i.e., age, race, and gender) were adjusted for the comparison of all characteristics except when
the demographic factors themselves were compared. In addition, we computed parametric
(Pearson’s) and nonparametric rank-based (Spearman’s) correlation coefficients between CRP
and important covariates.
We fitted a minimally adjusted model, adjusting for only key demographic factors, and a fully
adjusted model, adjusting for a comprehensive set of traditional risk factors. To build a
multivariate model, we used the backward elimination technique including all of the covariates
listed in Table 1 in the initial model. From the initial model, the variable with the largest p
value was removed 1 at a time until we reached the final parsimonious model with only
significant predictors (p ≤0.05). When a parsimonious set of predictors was established, we
retested whether any of the removed variables gained statistical significance when they were
reentered into the model to ensure that no variables were deleted erroneously in this sequential
process. In addition, variables (i.e., anthropometric measures in this case) based on our a priori
knowledge were also added to the model regardless of their statistical significance. In the final
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model, we assured that highly correlated variables were not entered together to avoid
multicollinearity. Model simplicity is also important to prevent overadjustment.12 For similar
or competing variables (e.g., BMI vs waist circumference, systolic vs diastolic blood pressure,
education vs income, serum creatinine vs glomerular filtration rate), we considered the relative
significance of each variable quantitatively and qualitatively (e.g., missing data proportion and
acceptability in clinical and practical settings).
We repeated regression analysis using continuous covariates and categorical covariates
separately to investigate potentially useful clinical thresholds for elevated CRP levels. We
adopted 2 categorizations: one is based on quartiles and the other is based on the cutpoints
recommended by the CDC and the American Heart Association (AHA).13 In both analyses,
age and BMI were treated as continuous variables to minimize residual confounding. From
regression analyses, odds ratios (ORs) were estimated together with the corresponding 95%
confidence intervals (CIs) to quantify the direction and magnitude of associations between
each predictor and the study outcome, controlling other variables.
In addition we performed several sensitivity analyses. First, we repeated the analysis for
nondiabetic participants to address the over-representation of diabetics among participants with
microalbuminuria. Second, we repeated the analysis using gender-specific definitions of
microalbuminuria (≥17 mg/day for men and ≥25 mg/day for women).14 Third, we performed
regression analysis using a combined outcome of microalbuminuria and macroalbuminuria to
better capture albuminuria as a continuous marker of kidney disease.
Statistical analyses were performed by SAS survey procedures (SAS version 9.1, SAS Institute,
Cary, North Carolina). 15 All analyses were weighted to incorporate the complex survey design
of NHANES with proper reflections of stratification and clustering. Six-year weights were
derived following analytic guidelines recommended by the National Center for Health
Statistics.16
Results
The study population consisted of 12,831 men and women drawn from the NHANES 1999 to
2004 after exclusion of 1,543 individuals whose urinary albumin or creatinine data were not
measured, 673 individuals whose CRP data were absent, and 285 individuals with
macroalbuminuria (Table 1). The study population included 52% women, with a mean age of
46 years. Seventy-one percent were non-Hispanic white, whereas 13% and 10% were Hispanic
and non-Hispanic African-American, respectively. The 1,378 participants (11%) with
microalbuminuria were more likely to be older, non-White, and of lower socioeconomic status
(assessed by education and income levels) than participants without microalbuminuria. The
prevalences of diabetes, current smoking, hypertension, heart failure, cerebrovascular disease,
peripheral vascular disease, and anemia were significantly higher in participants with
microalbuminuria compared with those without microalbuminuria. Unadjusted mean total,
low-density lipoprotein, and high-density lipoprotein cholesterol levels were similar among
participants with and without microalbuminuria (reflected in summary statistics), but these
differences were significant after adjustment for demographic factors (reflected in p values).
Pearson correlations coefficient measuring how CRP and the remaining individual variables
were linearly associated in our sample were low overall (all values p <0.1) (Table 2). Although
correlation coefficients slightly differed depending on the computing method adopted, some
common patterns were observed. CRP was positively correlated with age, triglyceride levels,
and urinary albumin-to-creatinine ratio (the raw variable for microalbuminuria). In contrast,
serum creatinine and high-density lipoprotein cholesterol consistently showed negative
correlation with CRP concentration.
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Multivariate logistic regression modeling identified 10 predictors of prevalent
microalbuminuria (age, race, education, current smoking status, history of heart failure, systolic
blood pressure, diabetes mellitus, peripheral vascular disease, anemia, and CRP) among study
participants (Table 3). Of the well-known traditional risk factors, diabetes, systolic blood
pressure, current smoking status, and history of heart failure demonstrated the strongest
associations with microalbuminuria. Of note, none of the lipid variables (i.e., triglycerides and
total, low-density lipoprotein, and high-density lipoprotein cholesterol) were significant in
multivariate models.
The mean CRP concentration among participants with microalbuminuria was 6.3 mg/L
compared with a mean concentration of 4.0 mg/L among controls (p = 0.0002) (Table 1). On
the basis of logistic regression analyses, CRP concentration was positively associated with
microalbuminuria (Table 2). In the multivariate model, a 1 mg/L increase in CRP was
associated with a 2% increased odds of microalbuminuria (OR 1.02, 95% CI 1.01 to 1.02, p =
0.0003). Nonlinear relationships assessed by squared and cubic terms of CRP were not
detected.
Using categorized CRP levels (quartiles and AHA/CDC recommendations), multivariate
models showed a positive trend for the association of CRP with microalbuminuria (Table 4).
Multivariable-level adjustments yielded attenuated associations in all conducted analyses.
Participants in the highest quartile of CRP concentration, ≥4.6 mg/L, demonstrated a significant
association with microalbuminuria (OR 1.35, 95% CI 1.06 to 1.72, p = 0.017) controlling for
a set of traditional risk factors. According to the AHA/CDC cutpoints, compared with persons
with CRP concentrations <1 mg/L, persons with CRP concentrations between 1 and 3 mg/L
and >3 mg/L were 1.15 times (95% CI 0.94 to 1.42) and 1.33 times (95% CI 1.08 to 1.65) more
likely to have microalbuminuria, respectively.
The association between diabetes and microalbuminuria was the strongest of any variable in
the model. We repeated analyses excluding diabetics to determine how sensitive the association
between CRP and albuminuria was to the diabetic status. Comparable discrimination was
observed (area under the curve [AUC] = 0.71 to 0.72) in all multivariate analyses, but the
associations were stronger in the highest levels of the multivariate models in Table 3 (ORs
increased to 1.82 and 1.57 compared with 1.35 and 1.33, respectively). Gender-specific
microalbuminuria cutpoints resulted in slightly attenuated association and discrimination (ORs
of 1.28 and AUC of 0.72), but increased statistical significance (i.e., smaller p ≤0.0006) for
CRP. Extending the endpoint to encompass microalbuminuria and macroalbuminuria together
(omitting the corresponding exclusion criterion) yielded respective ORs of 1.36 (p = 0.01) and
1.39 (p = 0.001), but with increased discrimination (AUC = 0.75).
Discussion
In this cross-sectional, population-based study, we found that CRP was significantly associated
with microalbuminuria. The association was especially strong with elevated levels of CRP.
Furthermore, CRP and microalbuminuria remained significantly associated after adjusting for
multiple variables previously reported as determinants of microalbuminuria. The results further
the hypotheses that vascular inflammation may be a determinant of microalbuminuria. The
findings add evidence to the link between early renal and cardiovascular disease. Furthermore,
CRP and urinary albumin excretion assays are inexpensive, minimally invasive, and
quantitative in nature, useful attributes not only in clinical research but also, possibly, in routine
patient care.
The combined 6-year data sets (1999 to 2004) of the NHANES provided a large study
population with substantial representation of women, African-Americans, and Hispanics. This
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sample size, nearly twice the previously largest study of this kind, allowed for detection of a
significant association between high CRP levels (i.e., >3 mg/L) (the currently recommended
clinical cutpoint) and microalbuminuria despite the majority of participants, as expected,
having CRP values well below this level. The NHANES also contained a wealth of data on
potential co-morbidities (e.g., diabetes, hyperlipidemia, systolic and/or diastolic hypertension,
peripheral vascular disease) that allowed for meaningful adjustments in our model. Although
our findings are consistent with previous studies that have reported an association between
CRP and albuminuria,1–7,9,10 these studies have not used equally comprehensive data and,
therefore, were often underpowered, not population-based, or not generalizable to the US
population.
Albuminuria, an established risk marker for progressive kidney disease, has now emerged as
a strong predictor of cardiovascular outcomes.17,18 Co-morbid conditions, such as diabetes
and hypertension, have been proposed as pathophysiologic missing links between incipient
kidney and heart disease. The demonstrated association between CRP and microalbuminuria,
however, suggests that another missing link—chronic inflammation—should be considered.
In addition, the emergence of CRP as a predictive biomarker for the development of
cardiovascular disease has raised the intriguing question of whether this inflammatory protein
is a “maker,” and not just a “marker,” of atherosclerosis.19–22 A similar link could be applied
between vascular inflammation and the glomerular, tubular, and interstitial injuries of chronic
kidney disease. Because microalbuminuria can be viewed as an early marker of endothelial
dysfunction,23–25 its connection to CRP is more intuitive than glomerular filtration rate,
although elevated CRP levels have also been associated with diminished creatinine clearances.
10
We have tried, in the overall model and with sensitivity analyses, to make meaningful
adjustments to the data to avoid overstating the association between CRP and
microalbuminuria. Nevertheless, there are certainly other factors involved with vascular
inflammation, known and unknown, that we have not accounted for, and our estimate of the
association between CRP and albuminuria, therefore, should be interpreted with caution. In
addition, in sensitivity analysis the large representation of diabetics among the cases limited,
but by no means eliminated, the validity of our results in nondiabetic populations.
Because NHANES are cross-sectional surveys, our findings only support an association
between CRP and microalbuminuria and should not yield any conclusions about causation.
Only a well-designed, fully powered, longitudinal study could attempt to answer the crucial
questions of whether elevated CRP causes microalbuminuria, microalbuminuria causes
elevated CRP levels, or, quite possibly, a third factor (or fourth, fifth, or sixth factor) leads to
clinically relevant levels of both markers. Advanced glycosylation end products, hypertension-
induced endothelial damage, increased plasma cholesterol concentrations, and activation of
mineralocorticoid receptors in high salt states are just a few potentially proximal factors that
could cause microalbuminuria and CRP elevation.
Acknowledgments
We thank the staff and participants of the NHANES study for their important contributions and valuable resources of
clinical research.
Drs. Bang, Gerber, and Mazumdar’s research was partially supported by the Tolly Vinik Trust through Weill Medical
College of Cornell University, New York, New York. Dr. Shoham is supported by Grant 5T-32HL007055-29 through
an National Heart, Lung, and Blood Institute, Bethesda, Maryland, institutional training grant in cardiovascular disease
epidemiology.
Kshirsagar et al. Page 5














1. Schalkwijk CG, Poland DC, van Dijk W, Kok A, Emeis JJ, Drager AM, Doni A, van Hinsbergh VW,
Stehouwer CD. Plasma concentration of C-reactive protein is increased in type I diabetic patients
without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence
for chronic inflammation. Diabetologia 1999;42:351–357. [PubMed: 10096789]
2. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and
cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000;35:469–476. [PubMed:
10692273]
3. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Nijpels G, Dekker JM, Heine RJ, Bouter LM,
Stehouwer CD. C-reactive protein and soluble vascular cell adhesion molecule-1 are associated with
elevated urinary albumin excretion but do not explain its link with cardiovascular risk. Arterioscler
Thromb Vasc Biol 2002;22:593–598. [PubMed: 11950696]
4. Paisley KE, Beaman M, Tooke JE, Mohamed-Ali V, Lowe GD, Shore AC. Endothelial dysfunction
and inflammation in asymptomatic proteinuria. Kidney Int 2003;63:624–633. [PubMed: 12631127]
5. Stam F, van Guldener C, Schalkwijk CG, ter Wee PM, Donker AJ, Stehouwer CD. Impaired renal
function is associated with markers of endothelial dysfunction and increased inflammatory activity.
Nephrol Dial Transplant 2003;18:892–898. [PubMed: 12686661]
6. Festa A, D’Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Inflammation and
microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis
Study. Kidney Int 2000;58:1703–1710. [PubMed: 11012904]
7. Nakamura M, Onoda T, Itai K, Ohsawa M, Satou K, Sakai T, Segawa T, Sasaki J, Tonari Y, Hiramori
K, Okayama A. Association between serum C-reactive protein levels and microalbuminuria: a
population-based cross-sectional study in northern Iwate, Japan. Intern Med 2004;43:919–925.
[PubMed: 15575240]
8. Stuveling EM, Hillege HL, Bakker SJ, Asselbergs FW, de Jong PE, Gans RO, de Zeeuw D. C-reactive
protein and microalbuminuria differ in their associations with various domains of vascular disease.
Atherosclerosis 2004;172:107–114. [PubMed: 14709363]
9. Stuveling EM, Bakker SJ, Hillege HL, Burgerhof JG, de Jong PE, Gans RO, de Zeeuw D. C-reactive
protein modifies the relationship between blood pressure and microalbuminuria. Hypertension
2004;43:791–796. [PubMed: 14967837]
10. Stuveling EM, Hillege HL, Bakker SJ, Gans RO, De Jong PE, De Zeeuw D. C-reactive protein is
associated with renal function abnormalities in a non-diabetic population. Kidney Int 2003;63:654–
661. [PubMed: 12631131]
11. Wald A. Tests of statistical hypotheses concerning several parameters when the number of
observations is large. Trans Am Mathematical Soc 1943;54:426–482.
12. Harrell, FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic
Regression, and Survival Analysis. New York: Springer; 2001.
13. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY,
Fortmann SP, Hong Y, Myers GL, et al. Markers of inflammation and cardiovascular disease:
application to clinical and public health practice: a statement for healthcare professionals from the
Centers for Disease Control and Prevention and the American Heart Association. Circulation
2003;107:499–511. [PubMed: 12551878]
14. Mattix HJ, Hsu CY, Shaykevich S, Curhan G. Use of the albumin/creatinine ratio to detect
microalbuminuria: implications of sex and race. J Am Soc Nephrol 2002;13:1034–1039. [PubMed:
11912263]
15. An A, Watts D. New SAS procedures for analysis of sample survey data. SAS Users Group
International 1998;23
16. Analytic and reporting guidelines: The National Health and Nutrition Examination Survey
(NHANES). [Accessed October 23, 2007]. Available at:
http://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/nhanes_analytic_guidelines_dec_2005.pdf
17. de Zeeuw D, Parving HH, Henning RH. Microalbuminuria as an early marker for cardiovascular
disease. J Am Soc Nephrol 2006;17:2100–2105. [PubMed: 16825327]
Kshirsagar et al. Page 6













18. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME,
Mitch WE, Brenner BM. Albuminuria, a therapeutic target for cardiovascular protection in type 2
diabetic patients with nephropathy. Circulation 2004;110:921–927. [PubMed: 15302780]
19. Paul A, Ko KW, Li L, Yechoor V, McCrory MA, Szalai AJ, Chan L. C-reactive protein accelerates
the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004;109:647–655.
[PubMed: 14744975]
20. Verma S, Kuliszewski MA, Li SH, Szmitko PE, Zucco L, Wang CH, Badiwala MV, Mickle DA,
Weisel RD, Fedak PW, Stewart DJ, Kutryk MJ. C-reactive protein attenuates endothelial progenitor
cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive
protein and cardiovascular disease. Circulation 2004;109:2058–2067. [PubMed: 15078802]
21. Blann AD, Lip GY. Effects of C-reactive protein on the release of von Willebrand factor, E-selectin,
thrombomodulin and intercellular adhesion molecule-1 from human umbilical vein endothelial cells.
Blood Coagul Fibrinolysis 2003;14:335–340. [PubMed: 12945874]
22. Nilsson J. CRP—marker or maker of cardiovascular disease? Arterioscler Thromb Vasc Biol
2005;25:1527–1528. [PubMed: 16055753]
23. Vervoort G, Wetzels JF, Lutterman JA, Bravenboer B, Berden JH, Smits P. Atrial natriuretic peptide-
induced microalbuminuria is associated with endothelial dysfunction in noncomplicated type 1
diabetes patients. Am J Kidney Dis 2002;40:9–15. [PubMed: 12087555]
24. Shestakova MV, Jarek-Martynowa IR, Ivanishina NS, Kuharenko SS, Yadrihinskaya MN,
Aleksandrov AA, Dedov II. Role of endothelial dysfunction in the development of cardiorenal
syndrome in patients with type 1 diabetes mellitus. Diabetes Res Clin Pract 2005;68:S65–S72.
[PubMed: 15955379]
25. Ochodnicky P, Henning RH, van Dokkum RP, de Zeeuw D. Microalbuminuria and endothelial
dysfunction: emerging targets for primary prevention of end-organ damage. J Cardiovasc Pharmacol
2006;47:S151–S162. discussion S172–S176. [PubMed: 16794452]
Kshirsagar et al. Page 7

























Kshirsagar et al. Page 8
Table 1
Mean ± SEM or prevalence (%) of risk factors by microalbuminuria case status in National Health and Nutrition






Age (yrs) 54.8 ± 0.75 45.1 ± 0.29 <0.0001*
Women 55.5% 52.0% 0.01*
White 67.0% 72.7% 0.003*
African-American 12.0% 9.9%
Hispanic 14.3% 12.9%
High education (>high school) 45.0% 54.9% 0.0006
Income (>$35,000 per year) 37.5% 52.6% <0.0001
Current smoker 21.9% 20.6% 0.0005
Family history of hypertension 25.5% 25.9% 0.39
Family history of diabetes 35.0% 28.6% 0.11
History of cardiovascular disease 11.4% 4.6% 0.007
History of heart failure 5.7% 1.7% <0.0001
Waist (cm) 100 ± 0.76 95.9 ± 0.26 0.008
Body mass index (kg/m2) 28.9 ± 0.30 28.0 ± 0.10 0.11
Systolic blood pressure (mm Hg) 135 ± 0.86 121 ± 0.33 <0.0001
Diastolic blood pressure (mm Hg) 74 ± 0.60 72 ± 0.23 0.23
Hypertension 55.8% 32.2% <0.0001
Diabetes mellitus 23.9% 6.1% <0.0001
Peripheral vascular disease 6.9% 2.2% 0.002
Total cholesterol (mg/dl) 203 ± 1.8 202 ± 0.59 0.02
HDL cholesterol (mg/dl) 51.7 ± 0.75 52.0 ± 0.29 0.01
LDL cholesterol (mg/dl) † 119 ± 2.1 121 ± 0.72 0.008
Triglycerides (mg/dl) † 162 ± 8.0 142 ± 2.2 0.20
Dyslipidemia‡ 9.8% 9.9% 0.86
Hemoglobin (mg/dl) 14.3 ± 0.08 14.5 ± 0.04 0.95
Anemia§ 5.0% 3.3% 0.10
Serum creatinine (mg/dl) 0.94 ± 0.001 0.88 ± 0.003 0.004
Glomerular filtration rate (ml/min/1.73
m2)
91.2 ± 2.9 93.6 ± 0.48 0.23
CRP (mg/L) 6.3 ± 0.42 4.0 ± 0.09 0.0002
All results were from weighted analyses to account for complex survey design.
*
Unadjusted p values. For all other p values, age, race, and gender are adjusted.
†
Measured only on subsamples, therefore different weight was used.
‡
Defined as taking an antihyperlipidemic drug, fasting LDL cholesterol ≥160 mg/dl, fasting HDL cholesterol ≤30 mg/dL, or nonfasting calculated
LDL (total cholesterol − HDL − triglycerides/5) ≥160 mg/dl.
§
Defined as hemoglobin <11 mg/dl or treatment.
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HDL = high-density lipoprotein; LDL = low-density lipoprotein.
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Table 2






Serum creatinine −0.02 −0.10
Glomerular filtration rate 0.0005 −0.04
Urinary albumin-to-creatinine ratio 0.08 0.13
Total cholesterol 0.007 0.14
High-density lipoprotein cholesterol −0.04 −0.13
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Table 3
Multivariate logistic regression model for microalbuminuria in National Health and Nutrition Examination
Surveys (NHANES) 1999 to 2004




OR (95% CI) p Value OR (95% CI) p Value
Age (yrs) 1.04 (1.03–1.04) <0.0001 1.01 (1.10–1.02) <0.0001
Women 1.05 (0.93–1.18) 0.44
White† 0.59 (0.50–0.69) <0.0001 0.73 (0.62–0.87) 0.0003
Low education‡ 1.16 (1.0–1.35) 0.05
Current smoker 1.43 (1.21–1.69) <0.0001
History of heart failure 1.53 (1.20–1.93) 0.0005
Body mass index 1.00 (0.98–1.01) 0.49
Systolic blood pressure 1.02 (1.02–1.03) <0.0001
Diabetes mellitus 3.41 (2.75–4.23) <0.0001
Peripheral vascular disease 1.40 (1.04–1.88) 0.026
Anemia 1.51 (1.05–2.15) 0.025
CRP 1.02 (1.01–1.03) <0.0001 1.02 (1.01–1.02) 0.0003
All results were from weighted analyses to account for complex survey design.
*
Significant predictors or suspected confounders selected a priori are included in the final model, n = 802 participants were not included due to missing
covariates.
†
There is no difference among African-American, Hispanic, and other races; therefore, these are combined into 1 group (reference).
‡
Education was used instead of income for socioeconomic status because income had high missing data.
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